Description

DIVAA^™isthefirstinvivosystemforthestudyofangiogenesisthatprovidesquantitativeandreproducIBLeresults.Duringthecourseoftheassay,implantgradesiliconecylindersclosedatoneend,calledangioreactors,arefilledwith20μlofTrevigen’sPathClear®basementmembraneextract(BME)premixedwithorwithoutangiogenic-modulatingfactors*.Theseangioreactorsarethenimplantedsubcutaneouslyinthedorsalflankofnudemice.Accompaniedwiththeonsetofangiogenesis,vascularendothelialcellsproceedtogrowintotheBMEandformvesselsintheangioreactor.Asearlyasninedayspost-implantation,thereareenoughcellstodetermineaneffectivedoseresponsetoangiogenicmodulatingfactors.Thesleekdesignoftheangioreactorprovidesastandardizedplatformforreproducibleandquantifiableinvivoangiogenesisassays.Comparedtotheplugassay,theangioreactorpreventsassayerrorsduetoabsorptionofthebasementmembraneextractbythemouse.Inaddition,theangioreactorusesonlyafractionofthematerialsconservingbothBMEandtestcompoundsused,anduptofourangioreactorsmaybeimplantedineachmouse,allowingforgreaterstatisticalpower.Trevigen’sDIVAAhasbeenusedinavarietyofinvestigations.

*ThePathClear®designationmeans:

• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPXXIVChapter71sterilitytest.
• NegativebyPCRtestfor:mycoplasma,17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.

Trevigen提供多种产品来测量氧化应激和DNA损伤。我们的彗星实验®产品线是为彗星试验，其中包括试剂，试剂盒，设备和分析软件的唯一完整和优化的商用平台。我们的TACS ®（Trevigen公司凋亡的细胞系统）产品已被广泛使用，并列举多年来，研究人员对他们的无与伦比的品质认可。